Methyl 2-cyano-3,11-dioxo-18-olean-1,12-dien-30-oate (CDODA-Me), a derivative of glycyrrhetinic acid, functions as a potent angiogenesis inhibitor.

The Journal of Pharmacology and Experimental Therapeutics
Xiufeng PangMingyao Liu

Abstract

Methyl 2-cyano-3,11-dioxo-18-olean-1,12-dien-30-oate (CDODA-Me), a triterpenoid acid derived synthetically from glycyrrhetinic acid, has been characterized as a peroxisome proliferator-activated receptor γ agonist with a broad range of receptor-dependent and -independent anticancer activities. Although CDODA-Me decreases the expression of some angiogenic genes in cancer cells, the direct effects of this compound on angiogenesis have not been defined. In this study, we have extensively investigated the activities of CDODA-Me in multiple angiogenesis assays. Our results showed that this agent inhibited vascular endothelial growth factor (VEGF)-induced proliferation, migration, invasion, and lamellipodium and capillary-like structure formation of human umbilical endothelial cells (HUVECs) in a concentration-dependent manner. Moreover, CDODA-Me abrogated VEGF-induced sprouting of microvessels from rat aortic rings ex vivo and inhibited the generation of new vasculature in the Matrigel plugs in vivo, where CDODA-Me significantly decreased the number of infiltrating von Willebrand factor-positive endothelial cells. To understand the molecular basis of this antiangiogenic activity, we examined the signaling pathways in CDODA-Me-treate...Continue Reading

References

Jan 27, 2000·Cell·D Hanahan, R A Weinberg
May 23, 2000·Nature·G HelmlingerR K Jain
Mar 16, 2004·Cancer Treatment and Research·Sybill Patan
May 4, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G Taraboletti, R Giavazzi
Dec 16, 2005·Nature·Peter Carmeliet
Dec 16, 2005·Nature·Napoleone Ferrara, Robert S Kerbel
Jan 13, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Adriana AlbiniGianfranco Fassina
May 3, 2006·Medicinal Research Reviews·Ana R QuesadaMiguel A Medina
Feb 27, 2007·Cardiovascular Research·Vishnu ChintalgattuLaxmansa C Katwa
Mar 3, 2007·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·B LaquenteJ R Germà
Mar 29, 2007·PPAR Research·Rinke StienstraSander Kersten
Aug 19, 2007·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Po-Hsun HuangRyozo Nagai
Aug 12, 2008·Current Clinical Pharmacology·Jeanine M RoodhartEmile E Voest
Nov 18, 2008·Cancer Treatment Reviews·Alex S StrimpakosKostas N Syrigos
Jul 8, 2009·International Journal of Cancer. Journal International Du Cancer·Sudhakar ChintharlapalliStephen Safe
Sep 24, 2009·Molecular and Cellular Endocrinology·Constantinos Christodoulides, Antonio Vidal-Puig
Jan 9, 2010·Seminars in Oncology·Janet E DanceyJoseph Purvis

❮ Previous
Next ❯

Citations

Nov 3, 2011·Nutrition and Cancer·Constantinos Giaginis, Stamatios Theocharis
Mar 13, 2014·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Rajapaksha Gedara Prasad Tharanga JayasooriyaGi-Young Kim
Feb 1, 2015·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Ying-Yun GuanChao Fang
Jan 30, 2013·The Journal of Pharmacy and Pharmacology·Benjamin LallemandJonathan Goole
Jul 10, 2020·Journal of Natural Medicines·Li-Hua MuCan Yan
Jun 7, 2012·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Xianmin MuLuyong Zhang
Nov 26, 2020·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·Jinfeng ShiGeorge Pak-Heng Leung

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.